Study Finds Good Adherence, Low ADE Rates With Oral DMTs
The multiple sclerosis (MS) therapeutic class boasts more than 20 disease modifying therapies (DMTs) that have various routes of administration. A recent study of oral therapies to treat relapsing-remitting MS (RRMS) found that they are well tolerated, have high adherence rates and have low rates of adverse events.
AllianceRx Walgreens Prime conducted the research in conjunction with Duquesne University School of Pharmacy. The study was presented at the Academy of Managed Care Pharmacy’s AMCP 2021 virtual conference in April.
Study Finds Fertility Program Prevents Medication Waste, Loss, Missed DosesREAD MORE
AbbVie Files Lawsuit Against Alternate Funding Company Payer Matrix Alleging ‘Fraudulent and Deceptive Scheme’READ MORE